SELLAS Life Sciences Group announced a positive review of the ongoing Phase 3 REGAL clinical trial of galinpepimut-S in acute myeloid leukemia by the Independent Data Monitoring Committee. The IDMC conducted a prespecified risk-benefit assessment of unblinded data from the study and has recommended that the trial continue without modifications. Based on a detailed analysis of all unblinded data, the IDMC projects with a high level of confidence that the interim analysis will occur by the fourth quarter of 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLS:
- SELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia
- Unusually active option classes on open June 12th
- SELLAS Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AML
- Sellas Life Sciences announces initial data in Phase 2a trial of SLS009
- Largest borrow rate increases among liquid names